Matching articles for "Synjardy"
Issue 1742 · November 24, 2025 Free
Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors (online only)

View the Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):e191-4 doi:10.58347/tml.2025.1742b
View the Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Issue 1742 · November 24, 2025
Noninsulin Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but most patients with type 2 diabetes eventually require glucose-lowering pharmacotherapy. An A1C goal of <7% (while minimizing hypoglycemia) is…

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):185-92 doi:10.58347/tml.2025.1742a
Diet, exercise, and weight loss can improve glycemic control, but most patients with type 2 diabetes eventually require glucose-lowering pharmacotherapy. An A1C goal of <7% (while minimizing hypoglycemia) is recommended for most patients to prevent or reduce the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy). An A1C target of <8% may be appropriate for patients who are older, have comorbid conditions, or are at risk of serious hypoglycemia-associated adverse events.
Issue 1742 · November 24, 2025 Free
Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors (online only)

View the Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):e191-4 doi:10.58347/tml.2025.1742b
View the Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Issue 1683 · August 21, 2023 Free
Empagliflozin (Jardiance) for Type 2 Diabetes in Children (online only)

The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin has been available for years alone ( Jardiance – Boehringer Ingelheim) and in combination with metformin (Synjardy) to improve glycemic…

Med Lett Drugs Ther. 2023 Aug 21; 65(1683):e137 doi:10.58347/tml.2023.1683e
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin has been available for years alone ( Jardiance – Boehringer Ingelheim) and in combination with metformin (Synjardy) to improve glycemic control in adults with type 2 diabetes. Both products have now been approved for use in children ≥10 years old. Empagliflozin is the second oral drug to become available in the US for treatment of type 2 diabetes in children; metformin has been available since 2000 for this indication. The injectable glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide (Victoza) and extended-release exenatide (Bydureon BCise) are also approved for use in children ≥10 years old.
Issue 1663 · November 14, 2022
Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia…

Med Lett Drugs Ther. 2022 Nov 14; 64(1663):177-84
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Issue 1599 · June 1, 2020 Free
In Brief: Trijardy XR - A New 3-Drug Combination for Type 2 Diabetes

The FDA has approved Trijardy XR (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, the dipeptidyl peptidase-4 (DPP-4) inhibitor…

Med Lett Drugs Ther. 2020 Jun 1; 62(1599):88
The FDA has approved Trijardy XR (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, and extended-release metformin, for oral treatment of type 2 diabetes in adults. Empagliflozin and linagliptin have been available in a fixed-dose combination as Glyxambi since 2015, and both have been available in 2-drug combinations with extended-release metformin for years (see Table 1).
Issue 1584 · November 4, 2019
Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes eventually require drug therapy. Treating to a glycated hemoglobin (A1C) concentration of <7% can…

Med Lett Drugs Ther. 2019 Nov 4; 61(1584):169-78
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes eventually require drug therapy. Treating to a glycated hemoglobin (A1C) concentration of <7% can prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular complications and death is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease (CVD), a history of severe hypoglycemia, diabetes-related complications, a limited life expectancy, or a long duration of disease.
Issue 1545 · April 23, 2018
Ertugliflozin for Type 2 Diabetes

The FDA has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin (Merck) for treatment of adults with type 2 diabetes, both alone (Steglatro) and in fixed-dose combinations with…

Med Lett Drugs Ther. 2018 Apr 23; 60(1545):70-2
The FDA has approved the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin (Merck) for treatment of adults with type 2 diabetes, both alone (Steglatro) and in fixed-dose combinations with metformin (Segluromet) and sitagliptin (Steglujan) . Ertugliflozin is the fourth SGLT2 inhibitor to be approved in the US. All four are available in combination with metformin and three are available in combination with a dipeptidyl peptidase-4 (DPP-4) inhibitor (see Table 3).
Issue 1513 · January 30, 2017
Comparison Table: SGLT2 Inhibitors (online only)

View the Comparison Table: SGLT2 Inhibitors

Med Lett Drugs Ther. 2017 Jan 30; 59(1513):e26
View the Comparison Table: SGLT2 Inhibitors
Issue 1512 · January 16, 2017
Drugs for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to…

Med Lett Drugs Ther. 2017 Jan 16; 59(1512):9-18
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to this target has been shown to prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular outcomes is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease, a history of severe hypoglycemia, diabetes-related complications or comorbidities, or a long duration of disease.
Issue 1484 · December 21, 2015
Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes

The FDA has approved Synjardy (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) and metformin (Glucophage , and others),…

Med Lett Drugs Ther. 2015 Dec 21; 57(1484):172-4
The FDA has approved Synjardy (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) and metformin (Glucophage , and others), for treatment of patients with type 2 diabetes not adequately controlled on either of these drugs alone or already being treated with both empagliflozin and metformin. It is the third SGLT2 inhibitor/metformin combination to be approved in the US.